Developer docs
API playgroundTry for free, no card

Search company profiles

Affimed

Full company profile

uuid00046ut

Namestring
Affimed
Websiteurl
affimed.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Affimed Therapeutics is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, and publicly listed on Nasdaq under the ticker AFMD. Founded in 2000, the company focuses on developing recombinant antibody therapeutics for the treatment of cancer and other diseases, operating specifically in the immuno-oncology and bispecific antibody segment of the biopharmaceutical market. With a workforce of 51-100 employees, Affimed pursues indications including BCMA-directed therapies, targeting a market projected to grow from $15.09 billion in 2025 to $44.29 billion by 2030 at roughly 24% CAGR.

The company's core technology centers on the engineering of bispecific antibodies designed to engage immune cells against tumor targets. Its product development operates within a small, specialized R&D footprint and relies on both equity financings and non-dilutive grant funding (e.g., German Federal Ministry of Research, Technology and Space) to advance pipeline candidates. Affimed has secured notable validation from major industry and financial investors, including a $96 million Roche-led round in 2018 and subsequent financings of $115 million in 2021 and $90 million in 2022.

Affimed's business model is consistent with pre-commercial biotech: revenue, where present, derives primarily from collaboration milestones, licensing, and grants rather than product sales. The company has not disclosed a commercial pricing model or marketed product in the available source data. Capital is sourced through public markets (Nasdaq listing) and a syndicate of specialized healthcare investors (OrbiMed, Novo Holdings, EQT Life Sciences, Aeris Capital, BioMedPartners, Perceptive Advisors), as well as strategic industry partners (Roche). Persistent net losses confirm ongoing cash burn typical of clinical development prior to commercial launch, and the absence of revenue mechanics disclosure limits visibility into a near-term commercial trajectory.

Short descriptiontext

Affimed Therapeutics is a publicly traded (Nasdaq: AFMD) clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing recombinant bispecific antibodies for cancer and other diseases, with 51-100 employees and a pipeline targeting BCMA-directed therapies in immuno-oncology.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMannheim, Germany
HQ citystring
Mannheim
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bispecific antibodies, cancer immunotherapy, antibody therapeutics, immuno-oncology drugs, recombinant antibodies
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Bispecific Antibody Therapeutics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Affimed Therapeutics develops recombinant antibody therapeutics, principally bispecific antibodies, for the treatment of cancer and other diseases. Its lead candidates engage immune effector cells (such as natural killer cells and T cells) to recognize and kill tumor cells. The company pursues both hematologic and solid tumor indications through its proprietary Immune Cell Engager (ICE) platform.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Bispecific Antibody Therapeutics Pipeline
CategoryBispecific Antibody Therapeutics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies that engage NK cells against tumors, directly comparable to Affimed's ICE platform in both mechanism and stage of development.

TypeDirect peer
Description

Pioneer in bispecific antibody technology (DuoBody platform) and a leading direct competitor in the bispecific antibody space, with approved and clinical-stage oncology assets that compete directly with Affimed's recombinant bispecific pipeline.

TypeDirect peer
Description

Develops bispecific and multifunctional antibodies using its Azymetric and other platforms, making it a direct modality peer to Affimed in engineered antibody therapeutics for oncology.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with a large bispecific antibody franchise and the historical strategic investor in Affimed (led $96M round in 2018); competes broadly with Affimed's oncology pipeline while also being a potential acquirer or partner.

TypeDirect peer
Description

Develops engineered bispecific antibodies using its XmAb platform for oncology and autoimmune indications, competing in the same bispecific antibody modality and partnership-driven business model as Affimed.

TypeEmerging player
Description

Clinical-stage biotech using Probody platform to create masked/conditional bispecific antibodies, partially overlapping with Affimed's bispecific antibody approach but differentiated by its tumor-microenvironment-activation strategy.

TypeBroad incumbent
Description

Large biopharmaceutical company with approved bispecific antibodies (e.g., Linvoseltamab, Odronextamab) in oncology, representing a well-capitalized incumbent competitor in the same therapeutic space as Affimed.

8Innate Pharma
TypeDirect peer
Description

Focused on NK cell-based immuno-oncology, including engagers and antibodies that mobilize innate immunity against tumors — a directly overlapping scientific approach with Affimed's innate cell engager (ICE) platform.

TypeEmerging player
Description

Early clinical-stage biotech developing NK cell engagers and tri-specific antibodies for cancer, with a mechanism that directly mirrors Affimed's NK-cell-engager approach but at an earlier stage.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, with overlapping oncology targets and a comparable development-stage profile to Affimed.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Affimed

Bispecific Antibody Therapeuticsaffimed.com

Affimed Therapeutics is a publicly traded (Nasdaq: AFMD) clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing recombinant bispecific antibodies for cancer and other diseases, with 51-100 employees and a pipeline targeting BCMA-directed therapies in immuno-oncology.

What Affimed does

Affimed Therapeutics is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, and publicly listed on Nasdaq under the ticker AFMD. Founded in 2000, the company focuses on developing recombinant antibody therapeutics for the treatment of cancer and other diseases, operating specifically in the immuno-oncology and bispecific antibody segment of the biopharmaceutical market. With a workforce of 51-100 employees, Affimed pursues indications including BCMA-directed therapies, targeting a market projected to grow from $15.09 billion in 2025 to $44.29 billion by 2030 at roughly 24% CAGR.

The company's core technology centers on the engineering of bispecific antibodies designed to engage immune cells against tumor targets. Its product development operates within a small, specialized R&D footprint and relies on both equity financings and non-dilutive grant funding (e.g., German Federal Ministry of Research, Technology and Space) to advance pipeline candidates. Affimed has secured notable validation from major industry and financial investors, including a $96 million Roche-led round in 2018 and subsequent financings of $115 million in 2021 and $90 million in 2022.

Affimed's business model is consistent with pre-commercial biotech: revenue, where present, derives primarily from collaboration milestones, licensing, and grants rather than product sales. The company has not disclosed a commercial pricing model or marketed product in the available source data. Capital is sourced through public markets (Nasdaq listing) and a syndicate of specialized healthcare investors (OrbiMed, Novo Holdings, EQT Life Sciences, Aeris Capital, BioMedPartners, Perceptive Advisors), as well as strategic industry partners (Roche). Persistent net losses confirm ongoing cash burn typical of clinical development prior to commercial launch, and the absence of revenue mechanics disclosure limits visibility into a near-term commercial trajectory.

Affimed firmographics

Firmographics
Name
Affimed
Website
https://affimed.com
Company type
Private
Founded year
2000
Headcount range
11–50 employees
Short description
Affimed Therapeutics is a publicly traded (Nasdaq: AFMD) clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing recombinant bispecific antibodies for cancer and other diseases, with 51-100 employees and a pipeline targeting BCMA-directed therapies in immuno-oncology.
Ownership category
akta.pro rank

Affimed industry classification

Industry
Product category
Bispecific Antibody Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Bispecific antibodies
  • Cancer immunotherapy
  • Antibody therapeutics
  • Immuno-oncology drugs
  • Recombinant antibodies

Where Affimed is headquartered

Location

Headquarters

HQ city
Mannheim
HQ country
Germany
HQ region
Europe

Markets served

Affimed business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Affimed product offering

Product offering

Core offering

Affimed Therapeutics develops recombinant antibody therapeutics, principally bispecific antibodies, for the treatment of cancer and other diseases. Its lead candidates engage immune effector cells (such as natural killer cells and T cells) to recognize and kill tumor cells. The company pursues both hematologic and solid tumor indications through its proprietary Immune Cell Engager (ICE) platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bispecific Antibody Therapeutics Pipeline

Companies that use Affimed

Customer profile

Ideal customer profiles2 records

Affimed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Affimed partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Affimed competitors and assessment

Company assessment

Direct peers

  • Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies that engage NK cells against tumors, directly comparable to Affimed's ICE platform in both mechanism and stage of development.
  • Genmab: Pioneer in bispecific antibody technology (DuoBody platform) and a leading direct competitor in the bispecific antibody space, with approved and clinical-stage oncology assets that compete directly with Affimed's recombinant bispecific pipeline.
  • Zymeworks: Develops bispecific and multifunctional antibodies using its Azymetric and other platforms, making it a direct modality peer to Affimed in engineered antibody therapeutics for oncology.
  • Xencor: Develops engineered bispecific antibodies using its XmAb platform for oncology and autoimmune indications, competing in the same bispecific antibody modality and partnership-driven business model as Affimed.
  • Innate Pharma: Focused on NK cell-based immuno-oncology, including engagers and antibodies that mobilize innate immunity against tumors — a directly overlapping scientific approach with Affimed's innate cell engager (ICE) platform.
  • MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, with overlapping oncology targets and a comparable development-stage profile to Affimed.

Broad incumbents

  • Roche: Global pharmaceutical incumbent with a large bispecific antibody franchise and the historical strategic investor in Affimed (led $96M round in 2018); competes broadly with Affimed's oncology pipeline while also being a potential acquirer or partner.
  • Regeneron: Large biopharmaceutical company with approved bispecific antibodies (e.g., Linvoseltamab, Odronextamab) in oncology, representing a well-capitalized incumbent competitor in the same therapeutic space as Affimed.

Emerging players

  • CytomX Therapeutics: Clinical-stage biotech using Probody platform to create masked/conditional bispecific antibodies, partially overlapping with Affimed's bispecific antibody approach but differentiated by its tumor-microenvironment-activation strategy.
  • GT Biopharma: Early clinical-stage biotech developing NK cell engagers and tri-specific antibodies for cancer, with a mechanism that directly mirrors Affimed's NK-cell-engager approach but at an earlier stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Affimed social profiles

Digital presence

Affimed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Affimed leadership team

Management profile

Number of profiles

Profiles8 records

Affimed funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Affimed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affimed

What does Affimed do?

Affimed Therapeutics develops recombinant antibody therapeutics, principally bispecific antibodies, for the treatment of cancer and other diseases. Its lead candidates engage immune effector cells (such as natural killer cells and T cells) to recognize and kill tumor cells. The company pursues both hematologic and solid tumor indications through its proprietary Immune Cell Engager (ICE) platform.

When was Affimed founded?

Affimed was founded in 2000. It employs 11 to 50 people.

Where is Affimed based?

Affimed is headquartered in Mannheim, Germany, in the Europe region.

Who are Affimed's main competitors?

Direct peers on record are Compass Therapeutics, Genmab, Zymeworks, Xencor, Innate Pharma and MacroGenics. Broad incumbents are Roche and Regeneron. Emerging players are CytomX Therapeutics and GT Biopharma.

Does Affimed have an API?

No public API is recorded for Affimed.

What industry is Affimed in?

Affimed's product category is Bispecific Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooBiotech Alert: Searches spiking for these stocks todaySearch interest in five biotech stocks surged today, with Inozyme Pharma leading at 1,125% and Affimed at 866%. The companies include Inozyme, Affimed, Acadia, UroGen, and Cabaletta Bio, each with described clinical-stage pipelines.BenzingaUS Stocks Edge Higher; Consumer Sentiment Falls In May - Healthcare Triangle (NASDAQ:HCTI)U.S. stocks traded slightly higher on Friday, with the Nasdaq Composite gaining 0.2%, S&P 500 rising 0.14%, and Dow up 0.09%, while the University of Michigan consumer sentiment index fell to 50.8 in May from 52.2 in April, below market estimates of 53.4. Individual stock movers included Affimed surging 390% following a Nasdaq delisting notice, Inozyme Pharma jumping 177% on news of BioMarin's $270 million acquisition offer, and Healthcare Triangle dropping 67%. Economic data showed U.S. import prices rising 0.1% month-over-month in April, building permits declining 4.7% to an 11-month low, and housing starts increasing 1.6%.GlobeNewswireAffimed Announces Filing for the Opening of Insolvency ProceedingsAffimed N.V. filed for insolvency proceedings with the Mannheim court on May 13, 2025, after failing to raise sufficient funds. The filing suspends and will delist its shares from Nasdaq. The outcome of the proceedings is uncertain.GlobeNewswireAffimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024Affimed N.V. will report its third quarter 2024 financial results and corporate update on November 14, 2024, via a conference call at 8:30 a.m. EST. The company, a clinical-stage immuno-oncology firm, will host the call with a webcast replay available for 30 days.GlobeNewswireAffimed to Report Second Quarter 2024 Financial ResultsAffimed N.V. announced it will report its second quarter 2024 financial results and corporate update on September 5, 2024, hosting a conference call at 8:30 a.m. EDT. The company, a clinical-stage immuno-oncology firm, will also provide a replay of the webcast for 30 days.Business InsiderAnalysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Affimed (AFMD) and Nurix Therapeutics (NRIX)Analysts reiterated buy ratings on R1 RCM, Affimed, and Nurix Therapeutics, with price targets ranging from $17 to $31. R1 RCM's consensus target is $17.13 (38.1% upside), Affimed's is $17.00 (140.5% upside), and Nurix's is $25.18 (52.5% upside).BenzingaWhy Is German Biotech Affimed Stock Soaring On Monday?Affimed N.V. announced longer follow-up data from the AFM24-102 study in non-small cell lung cancer on Saturday, showing encouraging clinical activity including objective responses in both EGFRwt and EGFRmut patient cohorts. In the EGFRwt cohort, 4 confirmed objective responses were observed among 15 evaluable patients with a disease control rate of 71% and median progression-free survival of 5.9 months. The company's shares surged 81.4% to $7.89 on Monday following the announcement.BenzingaWhy Affimed Shares Are SoaringAffimed N.V. announced additional follow-up data from the ongoing AFM24-102 study showing that in 17 EGFR wild-type NSCLC patients who had failed chemotherapy and PD-1/PD-L1 therapy, AFM24 combined with atezolizumab achieved four objective responses, with three responses ongoing beyond seven months and a progression-free survival of 5.9 months. HC Wainwright & Co. reiterated its Buy rating with a $10 price target following the announcement. Affimed shares rose 46.9% to $6.39 during Monday's session, with trading volume exceeding the stock's entire float.Yahoo7 Penny Biotech Stocks to Triple Your InvestmentSeven penny biotech stocks—FibroGen, Nuvectis, Relmada, Anixa, Genenta, Affimed, and Lipocine—are profiled for potential investment returns. FibroGen reported Q1 revenue of $56 million and net losses of $32 million, while Lipocine posted $3.5 million net income. Analysts assign target prices ranging from $5 to $32, with consensus targets for several firms.Business Insider7 Penny Biotech Stocks to Triple Your InvestmentSeven penny biotech stocks are profiled, including FibroGen, Nuvectis, Relmada, Anixa, Genenta, Affimed, and Lipocine, with their development pipelines and analyst price targets. FibroGen reported Q1 revenue of $56 million, down from $36 million, and net losses fell to $32 million. Analysts see potential for triple returns, though failure risk remains.